News Center
Home > News Center > Content Pages
Liquid Biopsy Continues to Prive Mettle for Ca Genes

CHICAGO -- The largest-ever study of liquid biopsies showed that half of patients with advanced cancers had tumor mutations that could be matched to FDA-approved cancer drugs, investigators reported here.

Almost two-thirds of the 15,191 patients had tumor mutations that could be matched to an approved drug or a treatment under evaluation in ongoing clinical trials. The commercially available blood test also identified resistance mutations that could inform decisions about selecting alternative cancer drugs.

For more information:

>> Returns a list of pages
Related Category
Promotion Products
  • Partners
  • Links
USCAP  |   CAP  |   IAP  |   TPIS  |   ASC  |   CAP-ACP  |   ASIP  |   AMP  |   ASCP  |   CAPA  |  
Home  |  News  |  Journals  |  Cases  |  Lectures  |  Experts  |  Telepath  |  Research  |  Conferences  |  Job_Position  |  Books  |  Sponsors
2009-2015 All Rights Reserved GoPath Diagnostics, LLC.